10-Q Filing

Processa Pharmaceuticals, Inc. CIK: 1533743 Q3 2019

Filing Information

Form Type	10-Q
Accession Number	`0001493152-19-017267`
Period End Date	20190930
Filing Date	20191114
Fiscal Year	2019
Fiscal Period	Q3
XBRL Instance	pcsa-20190930.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 88 Income Statement 52 Cash Flow Statement 86 Stockholders Equity 46

Balance Sheet 88 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	1.00M	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	-	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	-	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.74M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$504.30K	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	-	shares	Point-in-time
Due from related party	`DueFromRelatedPartiesCurrent`	$663.00	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	-	shares	Point-in-time
Due from related party	`DueFromRelatedPartiesCurrent`	$21.58K	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$220.28K	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$257.83K	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Total Current Assets	`AssetsCurrent`	$2.02M	USD	Point-in-time
Total Current Assets	`AssetsCurrent`	$725.25K	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	38.67M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	38.40M	shares	Point-in-time
Software	`CapitalizedComputerSoftwareGross`	$19.74K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	38.40M	shares	Point-in-time
Software	`CapitalizedComputerSoftwareGross`	$19.74K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	38.67M	shares	Point-in-time
Office equipment	`MachineryAndEquipmentGross`	$9.33K	USD	Point-in-time
Office equipment	`MachineryAndEquipmentGross`	$9.33K	USD	Point-in-time
Total Cost	`PropertyPlantAndEquipmentGross`	$29.07K	USD	Point-in-time
Total Cost	`PropertyPlantAndEquipmentGross`	$29.07K	USD	Point-in-time
Less: accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$11.69K	USD	Point-in-time
Less: accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$18.03K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$17.38K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$11.04K	USD	Point-in-time
Operating lease right of use assets, net of accumulated amortization	`OperatingLeaseRightOfUseAsset`	-	USD	Point-in-time
Operating lease right of use assets, net of accumulated amortization	`OperatingLeaseRightOfUseAsset`	$238.19K	USD	Point-in-time
Intangible assets, net of accumulated amortization	`IntangibleAssetsNetExcludingGoodwill`	$10.44M	USD	Point-in-time
Intangible assets, net of accumulated amortization	`IntangibleAssetsNetExcludingGoodwill`	$9.84M	USD	Point-in-time
Security deposit	`SecurityDeposit`	$5.54K	USD	Point-in-time
Security deposit	`SecurityDeposit`	$5.54K	USD	Point-in-time
Total Other Assets	`OtherAssetsNoncurrent`	$10.09M	USD	Point-in-time
Total Other Assets	`OtherAssetsNoncurrent`	$10.44M	USD	Point-in-time
Total Assets	`Assets`	$10.82M	USD	Point-in-time
Total Assets	`Assets`	$12.48M	USD	Point-in-time
Senior convertible notes	`SeniorNotesCurrent`	-	USD	Point-in-time
Senior convertible notes	`SeniorNotesCurrent`	$230.00K	USD	Point-in-time
Current maturities of operating lease liability	`OperatingLeaseLiabilityCurrent`	-	USD	Point-in-time
Current maturities of operating lease liability	`OperatingLeaseLiabilityCurrent`	$77.42K	USD	Point-in-time
Accrued interest	`InterestPayableCurrent`	-	USD	Point-in-time
Accrued interest	`InterestPayableCurrent`	$20.34K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$64.86K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$292.10K	USD	Point-in-time
Due to related parties	`DueToRelatedPartiesCurrent`	$25.73K	USD	Point-in-time
Due to related parties	`DueToRelatedPartiesCurrent`	-	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$123.67K	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$103.26K	USD	Point-in-time
Total Current Liabilities	`LiabilitiesCurrent`	$645.70K	USD	Point-in-time
Total Current Liabilities	`LiabilitiesCurrent`	$291.68K	USD	Point-in-time
Noncurrent operating lease liability	`OperatingLeaseLiabilityNoncurrent`	$166.74K	USD	Point-in-time
Noncurrent operating lease liability	`OperatingLeaseLiabilityNoncurrent`	-	USD	Point-in-time
Net deferred tax liability	`DeferredTaxLiabilitiesNoncurrent`	$1.69M	USD	Point-in-time
Net deferred tax liability	`DeferredTaxLiabilitiesNoncurrent`	$2.13M	USD	Point-in-time
Total Liabilities	`Liabilities`	$2.15M	USD	Point-in-time
Total Liabilities	`Liabilities`	$2.78M	USD	Point-in-time
COMMITMENTS AND CONTINGENCIES	`CommitmentsAndContingencies`	-	USD	Point-in-time
COMMITMENTS AND CONTINGENCIES	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, par value $0.0001, 1,000,000 and 10,000,000 shares authorized at September 30, 2019 and December 31, 2018, respectively; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, par value $0.0001, 1,000,000 and 10,000,000 shares authorized at September 30, 2019 and December 31, 2018, respectively; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, par value $0.0001, 100,000,000 and 350,000,000 shares authorized, respectively; 38,404,530 and 38,674,265 issued and outstanding at September 30, 2019 and December 31, 2018, respectively	`CommonStockValue`	$3.87K	USD	Point-in-time
Common stock, par value $0.0001, 100,000,000 and 350,000,000 shares authorized, respectively; 38,404,530 and 38,674,265 issued and outstanding at September 30, 2019 and December 31, 2018, respectively	`CommonStockValue`	$3.84K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$18.87M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$19.12M	USD	Point-in-time
Subscription receivable	`CommonStockSharesSubscriptions`	$1.80M	USD	Point-in-time
Subscription receivable	`CommonStockSharesSubscriptions`	-	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-7.62M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-10.21M	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$7.28M	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$8.67M	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$9.12M	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$10.51M	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$11.31M	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$9.70M	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$373.16K	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$8.50M	USD	Point-in-time
Total Liabilities and Stockholders' Equity	`LiabilitiesAndStockholdersEquity`	$10.82M	USD	Point-in-time
Total Liabilities and Stockholders' Equity	`LiabilitiesAndStockholdersEquity`	$12.48M	USD	Point-in-time

Income Statement 52 line items

Line Item	Tag	Value	Unit	Period
Research and development expenses	`ResearchAndDevelopmentExpense`	$2.48M	USD	3 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpense`	$1.80M	USD	3 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpense`	$611.61K	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpense`	$584.98K	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$419.03K	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.31M	USD	3 Qtrs
General and administrative expenses	`GeneralAndAdministrativeExpense`	$451.36K	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.22M	USD	3 Qtrs
Total operating expenses	`OperatingExpenses`	$1.06M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$3.78M	USD	3 Qtrs
Total operating expenses	`OperatingExpenses`	$1.00M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$3.02M	USD	3 Qtrs
Operating Loss	`OperatingIncomeLoss`	$-3.78M	USD	3 Qtrs
Operating Loss	`OperatingIncomeLoss`	$-3.02M	USD	3 Qtrs
Operating Loss	`OperatingIncomeLoss`	$-1.06M	USD	1 Quarter
Operating Loss	`OperatingIncomeLoss`	$-1.00M	USD	1 Quarter
Interest expense	`InterestExpense`	$12.97K	USD	3 Qtrs
Interest expense	`InterestExpense`	$8.32K	USD	1 Quarter
Interest expense	`InterestExpense`	$2.27K	USD	1 Quarter
Interest expense	`InterestExpense`	$154.38K	USD	3 Qtrs
Interest income	`InvestmentIncomeInterest`	$10.16K	USD	3 Qtrs
Interest income	`InvestmentIncomeInterest`	$6.46K	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$1.50K	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$10.89K	USD	3 Qtrs
Total other income (expense)	`OtherOperatingIncomeExpenseNet`	$-1.87K	USD	1 Quarter
Total other income (expense)	`OtherOperatingIncomeExpenseNet`	$-2.09K	USD	3 Qtrs
Total other income (expense)	`OtherOperatingIncomeExpenseNet`	$-768.00	USD	1 Quarter
Total other income (expense)	`OtherOperatingIncomeExpenseNet`	$-144.21K	USD	3 Qtrs
Net Operating Loss Before Income Tax Benefit	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-1.00M	USD	1 Quarter
Net Operating Loss Before Income Tax Benefit	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-1.06M	USD	1 Quarter
Net Operating Loss Before Income Tax Benefit	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-3.93M	USD	3 Qtrs
Net Operating Loss Before Income Tax Benefit	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-3.03M	USD	3 Qtrs
Income tax benefit	`IncomeTaxExpenseBenefit`	$-212.01K	USD	1 Quarter
Income tax benefit	`IncomeTaxExpenseBenefit`	$-141.25K	USD	1 Quarter
Income tax benefit	`IncomeTaxExpenseBenefit`	$-771.33K	USD	3 Qtrs
Income tax benefit	`IncomeTaxExpenseBenefit`	$-442.15K	USD	3 Qtrs
Net Loss	`NetIncomeLoss`	$-969.08K	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-863.52K	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-3.16M	USD	3 Qtrs
Net Loss	`NetIncomeLoss`	$-852.82K	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-750.83K	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-1.21M	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-2.58M	USD	3 Qtrs
Net Loss	`NetIncomeLoss`	$-1.10M	USD	1 Quarter
Net Loss per Common Share - Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-0.09	USD	3 Qtrs
Net Loss per Common Share - Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-0.02	USD	1 Quarter
Net Loss per Common Share - Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-0.02	USD	1 Quarter
Net Loss per Common Share - Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-0.07	USD	3 Qtrs
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	36.87M	shares	3 Qtrs
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	38.80M	shares	1 Quarter
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	38.72M	shares	3 Qtrs
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	38.67M	shares	1 Quarter

Cash Flow Statement 86 line items

Line Item	Tag	Value	Unit	Period
Common stock, shares transferred	`BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued`	-	shares	1 Quarter
Common stock, shares transferred	`BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued`	2.09M	shares	3 Qtrs
Common stock, shares transferred	`BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued`	2.09M	shares	1 Quarter
Conversion of senior convertible debt, value	`ConversionOfSeniorConvertibleDebtValue`	$230.00K	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-969.08K	USD	1 Quarter
Conversion of senior convertible debt, value	`ConversionOfSeniorConvertibleDebtValue`	$2.35M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-863.52K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-3.16M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-852.82K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-750.83K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-1.21M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-2.58M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-1.10M	USD	1 Quarter
Accrued interest converted into shares of common stock and warrants	`AccruedInterestConvertedIntoSharesOfCommonStockAndWarrants`	1.21M	shares	3 Qtrs
Accrued interest converted into shares of common stock and warrants	`AccruedInterestConvertedIntoSharesOfCommonStockAndWarrants`	126,741.00	shares	3 Qtrs
Depreciation	`Depreciation`	$6.33K	USD	3 Qtrs
Depreciation	`Depreciation`	$6.33K	USD	3 Qtrs
Amortization of right-of-use assets	`AmortizationOfRightofuseAssets`	$55.01K	USD	3 Qtrs
Amortization of right-of-use assets	`AmortizationOfRightofuseAssets`	-	USD	3 Qtrs
Amortization of debt issuance costs	`AmortizationOfFinancingCostsAndDiscounts`	$64.84K	USD	3 Qtrs
Amortization of debt issuance costs	`AmortizationOfFinancingCostsAndDiscounts`	-	USD	3 Qtrs
Amortization of intangible asset	`AmortizationOfIntangibleAssets`	$422.81K	USD	3 Qtrs
Amortization of intangible asset	`AmortizationOfIntangibleAssets`	$596.50K	USD	3 Qtrs
Amortization of intangible asset	`AmortizationOfIntangibleAssets`	$200.26K	USD	1 Quarter
Amortization of intangible asset	`AmortizationOfIntangibleAssets`	$198.83K	USD	1 Quarter
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	$-771.33K	USD	3 Qtrs
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	$-442.15K	USD	3 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$394.16K	USD	3 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$50.53K	USD	3 Qtrs
Payments made by an investor in satisfaction of their stock subscription receivable	`PaymentsMadeByInvestorInSatisfactionOfTheirStockSubscriptionReceivable`	-	USD	3 Qtrs
Payments made by an investor in satisfaction of their stock subscription receivable	`PaymentsMadeByInvestorInSatisfactionOfTheirStockSubscriptionReceivable`	$900.00K	USD	3 Qtrs
Prepaid expenses	`IncreaseDecreaseInPrepaidExpense`	$-37.55K	USD	3 Qtrs
Prepaid expenses	`IncreaseDecreaseInPrepaidExpense`	$240.87K	USD	3 Qtrs
Operating lease liability	`IncreaseDecreaseInOperatingLeaseLiability`	-	USD	3 Qtrs
Operating lease liability	`IncreaseDecreaseInOperatingLeaseLiability`	$59.00K	USD	3 Qtrs
Accrued interest	`IncreaseDecreaseInInterestPayableNet`	$8.59K	USD	3 Qtrs
Accrued interest	`IncreaseDecreaseInInterestPayableNet`	$89.52K	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-227.24K	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$29.33K	USD	3 Qtrs
Due (from)/to related parties	`IncreaseDecreaseInDueToRelatedParties`	$-32.39K	USD	3 Qtrs
Due (from)/to related parties	`IncreaseDecreaseInDueToRelatedParties`	$46.65K	USD	3 Qtrs
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$293.16K	USD	3 Qtrs
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$30.37K	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-1.24M	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-3.24M	USD	3 Qtrs
Purchase of intangible asset	`PaymentsToAcquireIntangibleAssets`	$1.78K	USD	3 Qtrs
Purchase of intangible asset	`PaymentsToAcquireIntangibleAssets`	-	USD	3 Qtrs
Purchase of software license	`PaymentsToAcquireSoftware`	-	USD	3 Qtrs
Purchase of software license	`PaymentsToAcquireSoftware`	$20.50K	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-22.28K	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	-	USD	3 Qtrs
Net proceeds from issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$2.97M	USD	3 Qtrs
Net proceeds from issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	-	USD	3 Qtrs
Transaction costs incurred on Senior Convertible Notes	`PaymentsOfDebtIssuanceCosts`	-	USD	3 Qtrs
Transaction costs incurred on Senior Convertible Notes	`PaymentsOfDebtIssuanceCosts`	$4.74K	USD	3 Qtrs
Payment of placement agent and legal fees associated with clinical funding commitment	`ProceedsFromPaymentsForOtherFinancingActivities`	$-117.34K	USD	3 Qtrs
Payment of placement agent and legal fees associated with clinical funding commitment	`ProceedsFromPaymentsForOtherFinancingActivities`	-	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	-	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$2.84M	USD	3 Qtrs
Net (Decrease)/Increase in Cash and Cash Equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-423.21K	USD	3 Qtrs
Net (Decrease)/Increase in Cash and Cash Equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-1.24M	USD	3 Qtrs
Cash and Cash Equivalents - Beginning of Period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$2.85M	USD	Point-in-time
Cash and Cash Equivalents - Beginning of Period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$2.42M	USD	Point-in-time
Cash and Cash Equivalents - Beginning of Period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.74M	USD	Point-in-time
Cash and Cash Equivalents - Beginning of Period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$504.30K	USD	Point-in-time
Cash and Cash Equivalents - End of Period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$2.85M	USD	Point-in-time
Cash and Cash Equivalents - End of Period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$2.42M	USD	Point-in-time
Cash and Cash Equivalents - End of Period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.74M	USD	Point-in-time
Cash and Cash Equivalents - End of Period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$504.30K	USD	Point-in-time
Right-of-use asset obtained in exchange for operating lease liability	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	-	USD	3 Qtrs
Right-of-use asset obtained in exchange for operating lease liability	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$293.20K	USD	3 Qtrs
Reduction in deferred lease liability	`ReductionInDeferredLeaseLiability`	$-9.96K	USD	3 Qtrs
Reduction in deferred lease liability	`ReductionInDeferredLeaseLiability`	-	USD	3 Qtrs
Operating lease liability	`OperatingLeaseLiabilities`	$303.16K	USD	3 Qtrs
Operating lease liability	`OperatingLeaseLiabilities`	-	USD	3 Qtrs
Recognize the exclusive license intangible asset acquired from CoNCERT	`RecognizeExclusiveLicenseIntangibleAssetAcquired`	-	USD	3 Qtrs
Recognize the exclusive license intangible asset acquired from CoNCERT	`RecognizeExclusiveLicenseIntangibleAssetAcquired`	$-11.04M	USD	3 Qtrs
Recognize deferred tax liability for basis difference for Intangible asset	`RecognizationOfDeferredTaxLiability`	$3.04M	USD	3 Qtrs
Recognize additional paid-in capital for consideration paid from the transfer of 2,090,301 common shares of Processa released by Promet to CoNCERT for Processa	`PaymentOfAdditionalPaidInCapitalForConsideration`	-	USD	3 Qtrs
Recognize additional paid-in capital for consideration paid from the transfer of 2,090,301 common shares of Processa released by Promet to CoNCERT for Processa	`PaymentOfAdditionalPaidInCapitalForConsideration`	$8.00M	USD	3 Qtrs
Net	`NonCashInvestingAndFinancingActivitiesNet`	-	USD	3 Qtrs
Net	`NonCashInvestingAndFinancingActivitiesNet`	-	USD	3 Qtrs
Conversion of $230,000 and $2,350,000 (respectively) of Senior Convertible Debt and related accrued interest into 126,741 and 1,206,245 shares (respectively) of common stock and warrants	`ConversionOfSeniorConvertibleDebtAndRelatedAccruedInterestIntoSharesOfCommonStockAndWarrants`	$258.93K	USD	3 Qtrs
Conversion of $230,000 and $2,350,000 (respectively) of Senior Convertible Debt and related accrued interest into 126,741 and 1,206,245 shares (respectively) of common stock and warrants	`ConversionOfSeniorConvertibleDebtAndRelatedAccruedInterestIntoSharesOfCommonStockAndWarrants`	$2.40M	USD	3 Qtrs
Common stock and stock purchase warrants (forfeited) issued in connection with a clinical trial funding commitment	`CommonStockAndStockPurchaseWarrantsForfeitedIssuedInConnectionWithClinicalTrialFundingCommitment`	$1.80M	USD	3 Qtrs
Common stock and stock purchase warrants (forfeited) issued in connection with a clinical trial funding commitment	`CommonStockAndStockPurchaseWarrantsForfeitedIssuedInConnectionWithClinicalTrialFundingCommitment`	$-900.00K	USD	3 Qtrs

Stockholders Equity 46 line items

Line Item	Tag	Value	Unit	Period
Common stock, shares exchanged	`BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued`	-	shares	1 Quarter
Common stock, shares exchanged	`BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued`	2.09M	shares	3 Qtrs
Common stock, shares exchanged	`BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued`	2.09M	shares	1 Quarter
Conversion of stock, costs	`ConversionOfStockNetOfCosts`	$4.74K	USD	1 Quarter
Conversion of stock, costs	`ConversionOfStockNetOfCosts`	-	USD	1 Quarter
Issuance of common stock units for cash, cost	`PaymentsOfStockIssuanceCosts`	-	USD	1 Quarter
Issuance of common stock units for cash, cost	`PaymentsOfStockIssuanceCosts`	$218.42K	USD	1 Quarter
Issuance of common stock units for a future research funding commitment, cost	`IssuanceOfCommonStockUnitsForFutureResearchFundingCommitmentCost`	$117.34K	USD	1 Quarter
Issuance of common stock units for a future research funding commitment, cost	`IssuanceOfCommonStockUnitsForFutureResearchFundingCommitmentCost`	-	USD	1 Quarter
Balance	`StockholdersEquity`	$7.28M	USD	Point-in-time
Balance	`StockholdersEquity`	$8.67M	USD	Point-in-time
Balance	`StockholdersEquity`	$9.12M	USD	Point-in-time
Balance	`StockholdersEquity`	$10.51M	USD	Point-in-time
Balance	`StockholdersEquity`	$11.31M	USD	Point-in-time
Balance	`StockholdersEquity`	$9.70M	USD	Point-in-time
Balance	`StockholdersEquity`	$373.16K	USD	Point-in-time
Balance	`StockholdersEquity`	$8.50M	USD	Point-in-time
Recognize the fair value of exclusive license intangible asset acquired from CoNCERT in exchange for 2,090,301 common shares of Processa held by Promet	`AdjustmentsToAdditionalPaidInCapitalOther`	$8.00M	USD	1 Quarter
Conversion of Senior convertible notes for common stock and stock purchase warrants	`StockIssuedDuringPeriodValueConversionOfUnits`	$258.93K	USD	1 Quarter
Conversion of Senior convertible notes for common stock and stock purchase warrants	`StockIssuedDuringPeriodValueConversionOfUnits`	$2.39M	USD	1 Quarter
Issuance of common stock units for cash, net of costs of $218,422	`StockIssuedDuringPeriodValueNewIssues`	$2.97M	USD	1 Quarter
Issuance of common stock units for a future research funding commitment, net of costs of $117,339	`StockIssuedDuringPeriodValueOther`	$-117.34K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$269.13K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$66.48K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$58.56K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$50.53K	USD	1 Quarter
Payments made by investor for clinical trial costs	`AdjustmentsToAdditionalPaidInCapitalPaymentMadeByInvestorForClinicalTrialCosts`	$504.07K	USD	1 Quarter
Payments made by investor for clinical trial costs	`AdjustmentsToAdditionalPaidInCapitalPaymentMadeByInvestorForClinicalTrialCosts`	$115.00K	USD	1 Quarter
Payments made by investor for clinical trial costs	`AdjustmentsToAdditionalPaidInCapitalPaymentMadeByInvestorForClinicalTrialCosts`	$280.93K	USD	1 Quarter
Pledged shares of common stock forfeited upon revised research funding commitment	`PledgeSharesOfCommonStockForfeitedUponRevisedResearchFundingCommitment`	-	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-969.08K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-863.52K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-3.16M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-852.82K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-750.83K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-1.21M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-2.58M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-1.10M	USD	1 Quarter
Balance	`StockholdersEquity`	$7.28M	USD	Point-in-time
Balance	`StockholdersEquity`	$8.67M	USD	Point-in-time
Balance	`StockholdersEquity`	$9.12M	USD	Point-in-time
Balance	`StockholdersEquity`	$10.51M	USD	Point-in-time
Balance	`StockholdersEquity`	$11.31M	USD	Point-in-time
Balance	`StockholdersEquity`	$9.70M	USD	Point-in-time
Balance	`StockholdersEquity`	$373.16K	USD	Point-in-time
Balance	`StockholdersEquity`	$8.50M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.